Radiosensitization using combinations of DNMT and HDAC inhibitors has been proposed based on the tumor-specific sensitization to therapeutics imparted by epigenetic drugs via induced tumor suppressor gene expression in epigenetically repressed chromatin, an uncommon occurrence in normal cells [144]. The gene discussed is HDAC9; the disease is neoplasm.